Tags

Type your tag names separated by a space and hit enter

Motor changes during sertraline treatment in depressed patients with Parkinson's disease*.
Eur J Neurol. 2008 Sep; 15(9):953-9.EJ

Abstract

BACKGROUND

Pharmacological interventions to treat depressive symptoms associated with Parkinson's disease (PD) are limited. Whether selective serotonine re-uptake inhibitors increase parkinsonism or have clinically significant interactions with antiparkinsonian drugs is unresolved.

PURPOSE

We used a naturalistic approach to prospectively investigate the long-term effects on motor status of adding sertraline in a large sample of community-dwelling PD patients with depressive symptoms.

METHODS

Main outcome measure was the motor part of the Unified PD Rating Scale (UPDRS) at baseline and at 1-, 3-, and 6-month follow-up. Secondary measures were the change in antiparkinsonian drugs expressed as total levodopa equivalent dose and the scores of the Hospital Anxiety and Depression Scale (HADS). Of the 374 patients included, 310 (82%) completed the study.

RESULTS

Treatment with sertraline (mean dose 66.0 +/- 29.8 mg) resulted in improvement in all UPDRS domains along with a significant decrease of the HADS scores. A modest but significant increase of the total dose of levodopa, without significant change of total levodopa equivalent dose, was observed. Almost 8% of patients discontinued medication for adverse events, mainly related to the gastrointestinal system.

CONCLUSIONS

Although worsening of tremor was observed in some patients, active management of depression with sertraline appears to have a positive impact on parkinsonism.

Authors+Show Affiliations

Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Autonomous University of Barcelona, Barcelona, Spain. jkulisevsky@santpau.catNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase IV
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18637826

Citation

Kulisevsky, J, et al. "Motor Changes During Sertraline Treatment in Depressed Patients With Parkinson's Disease*." European Journal of Neurology, vol. 15, no. 9, 2008, pp. 953-9.
Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, et al. Motor changes during sertraline treatment in depressed patients with Parkinson's disease*. Eur J Neurol. 2008;15(9):953-9.
Kulisevsky, J., Pagonabarraga, J., Pascual-Sedano, B., Gironell, A., García-Sánchez, C., & Martínez-Corral, M. (2008). Motor changes during sertraline treatment in depressed patients with Parkinson's disease*. European Journal of Neurology, 15(9), 953-9. https://doi.org/10.1111/j.1468-1331.2008.02218.x
Kulisevsky J, et al. Motor Changes During Sertraline Treatment in Depressed Patients With Parkinson's Disease*. Eur J Neurol. 2008;15(9):953-9. PubMed PMID: 18637826.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Motor changes during sertraline treatment in depressed patients with Parkinson's disease*. AU - Kulisevsky,J, AU - Pagonabarraga,J, AU - Pascual-Sedano,B, AU - Gironell,A, AU - García-Sánchez,C, AU - Martínez-Corral,M, Y1 - 2008/07/14/ PY - 2008/7/22/pubmed PY - 2008/12/23/medline PY - 2008/7/22/entrez SP - 953 EP - 9 JF - European journal of neurology JO - Eur J Neurol VL - 15 IS - 9 N2 - BACKGROUND: Pharmacological interventions to treat depressive symptoms associated with Parkinson's disease (PD) are limited. Whether selective serotonine re-uptake inhibitors increase parkinsonism or have clinically significant interactions with antiparkinsonian drugs is unresolved. PURPOSE: We used a naturalistic approach to prospectively investigate the long-term effects on motor status of adding sertraline in a large sample of community-dwelling PD patients with depressive symptoms. METHODS: Main outcome measure was the motor part of the Unified PD Rating Scale (UPDRS) at baseline and at 1-, 3-, and 6-month follow-up. Secondary measures were the change in antiparkinsonian drugs expressed as total levodopa equivalent dose and the scores of the Hospital Anxiety and Depression Scale (HADS). Of the 374 patients included, 310 (82%) completed the study. RESULTS: Treatment with sertraline (mean dose 66.0 +/- 29.8 mg) resulted in improvement in all UPDRS domains along with a significant decrease of the HADS scores. A modest but significant increase of the total dose of levodopa, without significant change of total levodopa equivalent dose, was observed. Almost 8% of patients discontinued medication for adverse events, mainly related to the gastrointestinal system. CONCLUSIONS: Although worsening of tremor was observed in some patients, active management of depression with sertraline appears to have a positive impact on parkinsonism. SN - 1468-1331 UR - https://www.unboundmedicine.com/medline/citation/18637826/Motor_changes_during_sertraline_treatment_in_depressed_patients_with_Parkinson's_disease__ L2 - https://doi.org/10.1111/j.1468-1331.2008.02218.x DB - PRIME DP - Unbound Medicine ER -